Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

PaperCitations, authors & open-access status

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 261 citations, 2020 year and closed oa status.

261
Citations
2020
Year
closed
OA Status

Related on ScholarIQ

Zhengyu Yang
Author
The Lancet Oncology
Journal
Advanced Breast Cancer Therapies
Topic
Advanced Breast Cancer Therapies
Topic
HER2/EGFR in Cancer Research
Topic
Breast Cancer Treatment Studies
Topic
470M+ articles · free account